Plus Therapeutics

05/28/2026

As comes to a close, our Plus Therapeutics and CNSide Diagnostics teams wore gray to honor brain cancer patients, their caregivers, advocates, and fellow researchers who work together every day to develop new diagnostics and treatments.

National Brain Tumor Society American Brain Tumor Association

05/26/2026

announces the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide cerebrospinal fluid assay.

The company believes that this cost-of-care analysis underscores that earlier LM diagnosis and therapeutic management enabled by reduces overall LM-related healthcare costs by approximately 40%. These savings are driven by earlier therapeutic intervention, improved treatment precision, and reduced hospitalizations.

The data were presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research 2026 Annual Meeting, where it was rewarded the Blue Ribbon Award as a top 5% presentation.

Full press release here: https://bit.ly/3RvFBGy

Link to poster: https://bit.ly/4uxKD45

About CNSide: https://bit.ly/49oPcoK

05/21/2026

The and CNSide Diagnostics teams will be at the American Society of Clinical Oncology Annual Meeting, beginning at the end of next week.

Email us at marketing@cnside-dx.com or respect@plustherapeutics.com to schedule an onsite meeting.

05/20/2026

This we’re highlighting our ongoing ReSPECT™ are advancing research for rare and difficult-to-treat CNS cancers, including , recurrent , and pediatric brain cancers.

Through targeted radiotherapeutic innovation, these trials aim to deliver precise treatment while sparing normal, healthy cells.

Learn more: www.respect-trials.com

05/19/2026

announces that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies to deliver a unique ex*****on platform for CNS .

The AI ex*****on platform is designed to integrate, organize, and derive actionable intelligence from longitudinal therapeutic, diagnostic and bioinformatic data sets generated across Plus’ CNS oncology technology programs.

Check out the full press release:

05/19/2026

announces that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies to deliver a unique ex*****on platform for CNS .

The AI ex*****on platform is designed to integrate, organize, and
derive actionable intelligence from longitudinal therapeutic, diagnostic and bioinformatic data sets generated across Plus’ CNS oncology technology programs.

Full press release here: bit.ly/4nDFyUX

05/15/2026

announces financial results for the first quarter ended March 31, 2026 and provides an overview of recent and upcoming business highlights.

Read the full release: bit.ly/4uqcRgM

05/14/2026

May is , an annual moment created by American Association for Cancer Research (AACR) to spread awareness of the efforts being made across the globe to develop essential cancer treatments for patients.

The team is dedicated to tackling the unmet need of improving outcomes for patients with central nervous system cancers, and that mission revolves around .

Learn more about our ongoing work to support cancer patients: bit.ly/4dq65kb

05/12/2026

Rx for Biotech, host Chris Leidli sits down with ' CEO, Dr. Marc Hedrick, and General Manager of CNSide Diagnostics, Russell Bradley, to explore a new, integrated approach to treating central nervous system cancers (including ( ) and )

In this episode, the group discusses:
- Why is so difficult to treat
- The role of the blood-brain barrier in limiting therapies
- How targeted can improve outcomes
- The importance of early detection and diagnostics
- How monitoring tumor cells can guide treatment decisions

Listen to their full discussion here: https://www.youtube.com/watch?v=K2Y06Q5Rntk

Why is brain cancer so hard to detect and treat - and what if we could change that?In this episode of Rx for Biotech, host Chris Leidli sits down with Marc H...

05/08/2026

announces a plenary session reviewing key clinical and translational data, including the Phase 1 ReSPECT-LM trial of REYOBIQ™ was presented at the 2026 American Association of Neurological Surgeons Annual Scientific Meeting.

This plenary session oral, presented by Henriette U. Balinda, PhD from UT Health San Antonio, underscored REYOBIQ’s potential as a differentiated targeted radiotherapeutic platform for CNS cancers.

Read the full release: https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-announces-oral-presentation-highlighting